Clinical Trials

22 enrolled

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT01110876 2021-08-25

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Phase 1/2 Terminated

21 enrolled 8 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00509431 2020-07-31

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

19 enrolled

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Phase 2 Withdrawn

CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

NCT00720356 2018-10-26

Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

115 enrolled 11 charts

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00335764 2018-07-02

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 1/2 Completed

92 enrolled 24 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00068367 2017-11-06

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

24 enrolled 7 charts

Sarcoma

Sarcoma, Neurofibrosarcoma

NCT00187486 2017-09-05

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

66 enrolled 8 charts

Glioblastoma, Gliosarcoma

NCT00045110 2017-08-17

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Phase 1/2 Completed

136 enrolled 27 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Meningioma, Oligodendroglioma, Gliosarcoma

NCT00086879 2017-07-27

Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme

110 enrolled

GastrointestinalGenitourinarySarcomaThoracic

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Phase 4 Completed

54 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

NCT00397384 2015-09-30

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

CNSGastrointestinalHead & NeckSarcomaThoracic

43 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors

NCT00112736 2015-06-15

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Phase 1/2 Completed

69 enrolled 12 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00525525 2014-11-14

AVF4120s

74 enrolled 7 charts

Glioblastoma, Gliosarcoma

NCT00609999 2014-07-16

Ph I Dasatinib + Erlotinib in Recurrent MG

47 enrolled

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00054496 2014-01-10

Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

Phase 2 Unknown

73 enrolled

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00672243 2013-08-07

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

32 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00039494 2013-08-02

Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

171 enrolled

Glioblastoma, Gliosarcoma

NCT00077454 2013-06-05

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

95 enrolled

Familial ependymoma, Astrocytoma, Medulloblastoma, Neuroblastoma, Osteosarcoma

NCT00387894 2013-06-04

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 2 Terminated

6 enrolled 10 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00671970 2013-05-13

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

57 enrolled 16 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00030498 2013-01-16

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

75 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anus Neoplasms, Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Ependymoma, Esophageal Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Breast Neoplasms, Male

NCT00274833 2012-12-06

Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

27 enrolled

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00227032 2012-03-06

Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

Phase 1 Terminated

10 enrolled

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors